• Press Release

Mount Sinai Researcher Awarded 2016 BRAIN Initiative Grant

  • New York, NY
  • (October 14, 2016)

Paul Slesinger, PhD, Professor of Neuroscience at the Icahn School of Medicine at Mount Sinai, has been awarded a 2016 National Institutes of Health (NIH) Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative grant to devise new tools and methods for rapidly identifying cells and genes that control certain brain circuits.

Announced today, the nearly $1 million grant to Mount Sinai is part of the third round of funding from the NIH to support the goals of the BRAIN Initiative.  Launched in 2013 by President Obama, the BRAIN Initiative is a large-scale effort to equip researchers with insights necessary for treating a wide variety of brain disorders like Alzheimer’s, schizophrenia, autism, epilepsy, and traumatic brain injury.   

“The World Health Organization estimates that devastating brain disorders affect more than 1 billion people worldwide, so there is a critical need to define the mechanisms behind brain disorders so that we may translate those findings into preventative or restorative interventions,” says Dr. Slesinger.  “I am honored to play a part in the BRAIN Initiative, which has already led to the development of innovative, state-of-the-art techniques, significantly accelerating the pace of neuroscience research.”  

Dr. Slesinger will work in collaboration with University of California, San Diego neuroscience researcher David Kleinfeld, PhD, to develop and validate an innovative neurotechnique for optically measuring the release of neuropeptides in cell-specific and circuit-specific processes in the brain.

Neuropeptides are essential neuromodulators in the brain that control cognition and sensorimotor processing through changes in vascular tone and blood flow in the nervous system.  Pharmacological and molecular genetic studies have implicated alterations in neuropeptide signaling as a contributor to brain dysfunctions, including migraines, addiction, motivation, and stress.  Although neuropeptides are widely expressed in the brain, remarkably little is known about when and where neuropeptides are released.  Monitoring the release of neuropeptides in real time in awake animals performing complex behaviors would be transformative, enabling the elucidation of the function of neuropeptides in regulating neural circuits in the brain.    

Drs. Kleinfeld and Slesinger developed cell-based neurotransmitter fluorescent engineered reporters (CNiFERs) to optically image neurotransmitter release in real time in vivo.  Under the leadership of Drs. Slesinger and Kleinfeld and supported by the BRAIN grant, the research team will develop and validate an innovative technique based on CNiFERs that were originally developed for detecting the release of classical, small molecule neurotransmitters.   

Specifically, three neuropeptide CNiFERs will be developed and used for test-bed validation projects within Mount Sinai’s laboratories:  

  • Orexin, which is important in sleep regulation as well as drug seeking and reinstatement
  • Somatostatin, which has been implicated in depression, motivation and learning
  • Vasoactive Intestinal Peptide, which has been implicated in neuroplasticity and learning.

“This award is an important and well-deserved honor for Dr. Slesinger, who is playing a key role in understanding mechanisms of alcoholism and other neuropsychiatric disorders so that the lives of people with these disorders can be improved,” says Paul Kenney, PhD, Chairman of the Department of Neuroscience at the Icahn School of Medicine at Mount Sinai.  “We are thrilled to play a part in this transformative initiative, which promises to make a huge impact on the lives of so many.”


About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and South Nassau Communities Hospital are ranked regionally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.